Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea
Article Information
vol. 28 no. 5 1083-1091
PubMed
Published By
Print ISSN
Online ISSN
History
- January 31, 2005
- September 27, 2004
- Published in print April 26, 2005.
Copyright & Usage
DIABETES CARE
Author Information
- David M. Kendall, MD1,
- Matthew C. Riddle, MD2,
- Julio Rosenstock, MD3,
- Dongliang Zhuang, PHD4,
- Dennis D. Kim, MD4,
- Mark S. Fineman, BS4 and
- Alain D. Baron, MD4
- 1International Diabetes Center and University of Minnesota, Minneapolis, Minnesota
- 2Section of Diabetes, Oregon Health & Science University, Portland, Oregon
- 3Dallas Diabetes and Endocrine Center, Dallas, Texas
- 4Amylin Pharmaceuticals, San Diego, California
- Address correspondence and reprint requests to Alain D. Baron, MD, Senior Vice President, Research, Amylin Pharmaceuticals, 9360 Towne Centre Dr., Suite 110, San Diego, CA 92121. E-mail: abaron{at}amylin.com
Statistics from Altmetric.com
Article usage
In this Issue
May 2005, 28(5)
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea
